Barclays
LIMN

Barclays’s Liminatus Pharma LIMN Stock Holding History

Barclays’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$474 Buy
+86
New +$743 ﹤0.01% 5014
2025
Q3 		– Sell
-4
Closed -$2.05K – 5788
2025
Q2 		$2.05K Buy
+4
New +$2.25K ﹤0.01% 5037

Other funds holding LIMN

CCA
Cygnus Capital Advisors Atlanta, Georgia $147M AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays's LIMN Position: Q2 2026 in Review

Barclays opened a new position in Liminatus Pharma (LIMN) in Q2 2026: 86 shares worth $474. The stake represents ﹤0.01% of the portfolio and ranks #5014 among its holdings. This is a return to the name: Barclays previously reported a position in LIMN as recently as Q2 2025.

Barclays first reported a position in LIMN in Q2 2025 and has held it in 2 quarters since. The position peaked at $2.05K in Q2 2025. 14 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • Barclays held 86 shares of Liminatus Pharma worth $474 as of Q2 2026.
  • Liminatus Pharma was a new Barclays position in Q2 2026.
  • Liminatus Pharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5014 holding.
  • Barclays first reported a position in Liminatus Pharma in Q2 2025 and has held it in 2 quarters since.
  • Barclays's Liminatus Pharma position peaked at $2.05K in Q2 2025.
  • 14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.